Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13058-015-0598-8 http://scihub22266oqcxt.onion/10.1186/s13058-015-0598-8 C4480505!4480505!26111812     free     free     free       Breast+Cancer+Res 2015 ; 17 (1): ä Nephropedia Template TP {{tp|p=26111812|t=2015. Metformin in breast cancer - an evolving mystery |pdf=|usr=}}{{26111812}} gab.com Text Metformin in breast cancer - an evolving mystery JO: Breast Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26111812 #FOAvip Metformin, a diabetes drug with well-established side effect and safety profiles, has been widely studied for its anti-tumor activities in a number of cancers, including breast cancer. But its mechanism of action in the clinical arena remains elusive. In a window of opportunity trial of metformin in non-diabetic breast cancer patients, Dowling and colleagues examined both the direct actions of the drug on cancer cells (as mediated by AMP kinase), as well as its indirect actions (as mediated by circulating insulin). The data suggest that short-term administration of metformin in this setting has anti-tumor effects significantly involving the indirect, insulin-dependent pathway. The role of the direct pathway remains to be determined. This study represents an important step forward in establishing one of several possible mechanisms for metformin, information that will be useful in determining candidate biomarkers to evaluate in large clinical trials of metformin, such as the ongoing NCIC CTG MA.32 trial of adjuvant metformin. The potential significance of these data for metformin in the treatment of breast cancer is discussed here. Twit Text FOAVip Metformin in breast cancer - an evolving mystery ????Breast Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26111812 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26111812 #FOAvip English Wikipedia <ref>{{Cite pmid|26111812}}</ref> Metformin in breast cancer - an evolving mystery #MMPMID26111812 Camacho L; Dasgupta A; Jiralerspong S Breast Cancer Res 2015[]; 17 (1): ä PMID26111812show ga Metformin, a diabetes drug with well-established side effect and safety profiles, has been widely studied for its anti-tumor activities in a number of cancers, including breast cancer. But its mechanism of action in the clinical arena remains elusive. In a window of opportunity trial of metformin in non-diabetic breast cancer patients, Dowling and colleagues examined both the direct actions of the drug on cancer cells (as mediated by AMP kinase), as well as its indirect actions (as mediated by circulating insulin). The data suggest that short-term administration of metformin in this setting has anti-tumor effects significantly involving the indirect, insulin-dependent pathway. The role of the direct pathway remains to be determined. This study represents an important step forward in establishing one of several possible mechanisms for metformin, information that will be useful in determining candidate biomarkers to evaluate in large clinical trials of metformin, such as the ongoing NCIC CTG MA.32 trial of adjuvant metformin. The potential significance of these data for metformin in the treatment of breast cancer is discussed here. äMetformin in breast cancer - an evolving mystery (epmc).pdf DeepDyve Pubget Overpricing